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 Abstract 
Background: Clarithromycin-based regimens are commonly used as a first line therapy in 
Helicobacter pylori positive patients, however treatment failures associate with resistance 
to clarithromycin are increasing worldwide. 
Objectives: to evaluate the use of stool samples to detect the presence of Helicobacter 
pylori DNA, while concurrently detecting mutations associated with the clarithromycin 
resistance. 
Methods: 292 Helicobacter pylori negative and positive patients were included.  DNA was 
extracted from raw stools. TaqMan real-time PCR amplification was used to detect the 
presence of Helicobacter pylori as well as predict the genotype of the organism and the 
related outcome of patients treated with clarithromycin. Patients were also tested by Urea 
breath test and subjected to esophagogastroduodenoscopy followed by histology, culture 
and rapid urease test, to obtain a consensus patient infection status. 
Results: Out of 292 total stool samples, 228 were deemed true positives. The sensitivity 
and specificity for Helicobacter pylori detection by PCR was 92.8% and 77.6% 
respectively. Out of 239 samlples  that resulted Hp positive with PCR, 213 were also 
sequenced, 36% showed point mutations associated with CLA resistance (A2142C, 
A2142G, A2143G). The final correlation of genotype and eradication was 83.5%. 
 Conclusions: Helicobacter pylori DNA can be detected in human stool specimens with a 
high sensitivity, and therefore can be used to determine its presence without obtaining 
biopsy sample. Moreover, the genotypic resistance to clarithromycin can be detected 
without obtaining a biopsy sample in order to choose the right therapeutic approach. 
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Chapter 1- Introduction 
 
1.1 Helicobacter pylori infection epidemiology and colonization 
Helicobacter pylori (H. pylori) is a gram-negative bacterium that has colonized the human 
stomach for 58.000 years. During this period it has developed highly specific and sensitive 
mechanisms of adaptation to survive in the acid environment of the stomach that is 
usually inhospitable for other bacteria (1). H. pylori infects over 50% of the world 
population and it has been demonstrated that the predominant composition of its 
molecular structure is different among different geographic areas and that its distribution 
follows known human migration patterns (2). Currently there are two main epidemiological 
patterns and their distribution follows the level of economic and social development of 
each country. In more developed countries (e.g. Western Countries) there is an increasing 
prevalence of the infection with age ranging from 5% in the first decade to 50-60% in the 
sixth decade. Less developed countries (e.g. Asia and Africa) show a high prevalence of 
the infection already present in the first decade (50-60%) and only a little increase with 
age (3). The prevalence of the infection also varies with a low prevalence (30%) in 
industrialized countries compared to high prevalence in less industrialized countries (80-
90%) (4). The infection is acquired during childhood but the route of transmission is still 
unclear. The age of acquisition depends on the prevalence of the infection in the country 
considered and relates to social conditions and public health structure. Children from 
developed countries show a higher age of seroconversion (when the infection becomes 
visible in blood samples) and the acquisition rate is lower than in developing countries. 
These differences in age of acquisition relates to different social and environmental 
conditions such as low standard of hygiene, overcrowding and promiscuity. The same risk 
factors are also related to the probability of reinfection which is higher in developing 
countries than in developed countries (70% vs 1-2% respectively). 
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Despite multiple attempts to find the route of transmission of this infection, the exact 
mechanism is still unknown. Humans, animals and environment are all possible 
responsible for H. pylori transmission. The first route, from human to human, is generally 
recognised as the most important source of infection and it is believed that the organism is 
acquired in childhood from family members. In countries with a poor public hygiene a role 
could be played by the environment (contaminated water or food) or animals, although 
there is a very little evidence that supports the latter (5). 
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1.2 Helicobacter pylori infection and metabolism 
H. pylori enters the body via the mouth. There are many factors that can limit bacteria 
colonization in the stomach such as acidity, host innate and adaptive immunity, peristalsis 
and nutrient availability. H. pylori has developed numerous ways to deal with these 
problems and survive in an hostile environment. 
Once in the stomach the bacterium, due to its particular shape and motility, is able to 
move toward higher pH zones (less acid) and bind to receptors on the surface of gastric 
epithelial cells in order to penetrate the gastric mucosa. H. pylori is also able to bind the 
gastric cells due to the presence on his surface of lipopolysaccharides (LPS) called 
“adhesins”. Many adhesins have been identified in this process but the principal one is 
called BabA (blood group antigen-binding adhesin) and it is able to bind a specific group 
antigen (Lewis b blood group antigen) that is located on gastric tissue leading to a strong 
adhesion of the pathogen to the gastric mucosa. This molecule has a structure that 
mimics that of some host antigen and therefore it can escape the control of the immune 
system (6). The adhesion of BabA to the gastric epithelium facilitates the secretion of 
intracellular proteins that are able to damage the gastric cells with an effect that is called 
“cytotoxic” leading to H. pylori survival. At the same time the pathogen produces a large 
amount of a particular enzyme called urease that is responsible of acid neutralization. This 
enzyme breaks down the urea in the stomach to carbon dioxide (CO2) and ammonia. The 
latter, who is alkaline, contributes to neutralising the stomach acid, therefore the 
bacterium can survive and replicate. H. pylori is therefore able to live in a hostile 
environment such as the stomach and is also capable of reducing the host immune 
response by secreting several proteins and to compete with other bacteria with a complex 
system that facilitates the uptake of nutrients (7). 
All these mechanisms explain how the pathogen is able to survive in the gastric  
environment but they are not useful to understand the mechanisms of action that leads to 
many gastric pathologies that are related to it. In fact, its ability in determining gastric 
10 
 
lesions seems to be linked to the presence of a DNA fragment located in the inner part of 
the bacteria chromosome called Cag PAI (cytotoxin associated pathogenicity island). One 
of the gene that is present in this “isle” is called CagA (cytotoxin associated gene A) and 
codifies for the homonymous protein cagA. It has been demonstrated that this protein has 
an important role in activating the host immune response. Subjects that are cagA positive 
develop a higher immune response and therefore are at higher risk of developing gastric 
pathologies (e.g. peptic ulcer or gastric adenocarcinoma). In association with cagA, H. 
pylori can express another protein that presents a high cell toxicity called “vacA” 
(vacuolizing-associated gene A). The expression of the cagA protein on the surface of H. 
pylori defines two different type of bacteria with different ability of creating damage in the 
stomach: H. pylori cagA positive and vacA positive (type I) that creates a bigger 
inflammation and is highly associated with peptic ulcer and colonises the gastric 
epithelium with high bacterial density. Whereas H. pylori cagA negative (type II) although 
it can express vacA on its surface, it is not toxigenic for gastric epithelium and it is less 
related to the presence of gastric pathologies (8). 
The host response to the presence of the infection contributes to the damage of the 
gastric epithelium itself: it activates the immune cell response and the local releases of 
toxic substances (e.g. oxygen radicals) that contributes to the tissue damage. 
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1.3 Helicobacter pylori clinical features 
Since its discovery in 1982, interest in the role of this bacterium in determining human 
pathologies has grown and it has been recognised as one of the key factor responsible for 
many gastric and extra-gastric pathologies. Stomach colonization is usually acquired 
during childhood and, if not treated, persists for the entire life. The route of transmission of 
the infection is unclear but some evidence has suggested that oral-oral, gastric-oral, and 
faecal-oral could be plausible ways of transmission (9). 
In some individuals H. pylori colonises the stomach for many decades without 
consequences but, more often, it is responsible for pathological changes in the gastric 
mucosa that lead to several diseases including peptic pathologies (gastric and duodenal 
ulcer) and malignancies such as non-cardia gastric adenocarcinoma and gastric mucosal 
associated lymphoid tissue (MALT) lymphoma (10). The causal link between the infection 
and the occurrence of peptic ulcer disease is supported by the correlation of its 
eradication and the resolution of ulceration achieved after the treatment, which has been 
shown not only to heal ulcers but also to prevent their recurrence. The same close 
relationship can be seen between long term colonization by the pathogen and the 
development of gastric malignancies (especially MALT lymphoma) that, if detected at an 
early stage, can regress after H. pylori eradication (11). While these relationships are well 
established, there is still an ongoing debate about the role of the pathogen and the real 
benefit that is achieved after its eradication in other clinical conditions such as esophageal 
reflux disease and non-ulcer dyspepsia. However, it is now clear that the role of H. pylori 
as a causal agent of many diseases is not limited to gastric pathologies but can also be 
related to infection and respiratory disorders such as Chronic Obstructive Pulmonary 
Disease (COPD), asthma, cardiovascular diseases, immune-mediated allergic disorders, 
hematological and endocrine disorders (9). 
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1.3.1 Gastric disorders 
 
1.3.1.1 Peptic ulcer disease 
 
The first association with H. pylori and gastric pathologies was discovered in 1983, then 
the pathogen was recognized as the causal agent of gastritis and ulceration (12). Peptic 
ulcer is a lesion of the gastrointestinal lining (mucosa) that can be localized in the stomach 
(gastric ulcer) or in the duodenum (duodenal ulcer). Several factors have been 
demonstrated to be linked to the development of these diseases: smoking habits, genetic 
predisposition and gender (males seem to be more susceptible than females). Moreover, 
the role played by external factors such as the chronic administration of anti-inflammatory 
drugs (FANS) can increase the risk of developing peptic ulcers and the risk of bleeding in 
presence of pre-existing gastrointestinal lesions (13). 
The leading mechanism in the development of an ulcer is the loss of balance between 
gastric protective factors (e.g. production of mucus) and elements that are able to attack 
the gastrointestinal mucosa (e.g. gastric acid). The presence of H. pylori can facilitate this 
disequilibrium and determine the occurrence of peptic ulcers. There are no specific 
symptoms that can be surely related to the presence of the pathogen, however epigastric 
pain or burning, bloating and dyspepsia (a feeling of slow digestion) are common in 
patients with non-complicated peptic ulcers. Sometimes subjects can develop a massive 
active bleed that can be seen both as hematemesis (the vomiting of blood) and/or melena 
(dark feces with digested blood). 
However, not every person infected will develop clinical symptoms, only about 20% of 
patients with H. pylori infection will develop peptic ulcer disease while the rest of persons 
colonized by the pathogen will remain symptom free (9). 
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1.3.1.2 Gastric cancer 
 
In 1994 the International Agency for Research on Cancer (IARC) classified H. pylori as a 
class I carcinogen, they admit that a long term colonization can be responsible of the 
development of gastric malignances such as adenocarcinoma and MALT lymphoma (14). 
The presence of H. pylori constitutes a chronic inflammatory stimulus on the gastric layer 
that lead to the development of an immune response that consists in small aggregates of 
inflammatory cells (lymphoid aggregates). Those immune aggregates progressively 
acquire an autonomous growth potential through the accumulation of genetic alterations 
leading to the development of tumor tissue. In some cases the presence of the infection 
and MALT lymphoma is associated with other haematological malignancies (e.g. diffuse 
large B-cell lymphoma) (15) suggesting that other neoplastic lesions can originate from a 
previous H. pylori infection following a prolonged contact. Moreover, recent studies 
demonstrates a correlation between H. pylori eradication and the a complete resolution of 
MALT lesions and diffuse large B-cell lymphoma with concomitant MALT lesions 
confirming a close relationship between the three and the importance to test and treat 
subjects with suspected or known gastric lymphoid pathology (16). 
 
1.3.2 Extra-gastric disorders 
 
Several attempts have been made to explore the relationship between H. pylori infection 
and extra-gastric disorders, however studies gave contradictory results so far (17). An 
example is given by the presence of conflicting data on the relationship between H. pylori 
and esophageal diseases.  The uncertainties about the real effect of the pathogen derive 
from different effects that can be determined on gastric acid production related to its 
localization in the gastric mucosa and its effect on acid production. Studies suggested that 
the presence of H. pylori, the subsequent development of chronic changes in gastric 
mucosa (gastric atrophy) and the related reduced acid production are protective factors 
for the development of esophageal pathologies such as esophagitis and reflux disease. 
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Therefore its eradication and the consequent healing of the gastric mucosa are a primary 
cause of esophageal pathologies, whereas other studies showed that its eradication only 
reveals a pre-existing condition (18). In recent years several studies claimed a role for the 
pathogen in the development of clinical conditions of many different extra-gastric systems 
(e.g. respiratory, cardiovascular, immune and endocrine systems) however, there are still 
conflicting results on the real impact of the infection outside the gastric environment (9). 
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1.4 Helicobacter pylori genome 
The H. pylori genome is about 1.60 Mbp long, constituted by numerous genes coding 
outer membrane proteines and putative adhesions, testifyng to the importance of 
adhesion in its biology. Many adhesins have been identified, but the principal is Bab A, 
which binds the Lewis b blood group antigen (Leb) expressed on gastric tissue. In addition 
to Bab A, also the Sialic acid-binding adhesin (Sab A) is important to adhesion because it 
bends sialyl-Lewis x blood group antigen (sialyl-Lex) which is expressed after chronic 
inflammation induced by H. pylori. The interaction between gastric sialyl-Lex and SabA 
determines the colonization density of patients who do not express gastric Leb or who 
express it weakly.  
Other functions of H. pylori genome is to modulate the urease activity in order to obtain a 
correct modulation of the bacterial intracellular pH while transiently present in an acid 
environment. Urease is one of the most abundant proteins produced by H. pylori, 
comprising about 10-15% of the total protein content (9). 
Another important area of the H. pylori genome is the Vac A gene, coding for the 
vaculating cytotoxin A protein. This is present in nearly all strains of H. pylori but only half 
of them secrete Vac A as a mature protein. As previously pointed out, Vac A is released 
by H. pylori as a free solubile toxin and is activated by exposure to acid. Vac A affects 
different host cells like gastric epithelial cells, macrophages neutrophilis, mast cells, T cell, 
and goblet cells. It interacts with several cellular compartiements resulting in cell 
apoptosis or necrosis, with the patophysiological effects depending upon cell type affected. 
Cag A also interferes with host cell signaling, leading to altered morphology, cell division 
or apoptosis. The presence of the Cag A denotes susceptibility to a more severe 
pathology, therefore H. pylori strains are classified into Type I (Cag PAI rich) and Type II 
(lacking Cag PAI) (9). 
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H. pylori has a high degree of genetic diversity, which has been attributed to horizontal 
transfer, high mutations rate and impaired DNA repair (19). The bacteria is capable to 
develop antibiotic resistance trough several mechanisms; one of them leads to amoxicillin 
(AMX) resistance by the expression of active efﬂux pumps that excrete drugs and point 
mutationsn the pbp1A gene that may contribute to the mechanisms of resistance to beta-
lactams. 
Several mutations have been detected also for Clarithromycin (CLA) resistance; it has 
been found that three point mutations—namely A2143G, A2142G and A2142C—are 
responsible for >90% of cases of primary CLA resistance in H. pylori strains isolated in 
Western countries (20). The H. pylori proteome suggests that all its evolution went 
through implementation of adhesive mechanisms (eg. BabA) and resistance mechanisms, 
and further investigations of his host-pathogen interaction will yeld other important 
informations on its bioechology. 
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1.5 Helicobacter pylori diagnosis 
At least 50% of the world’s human population has H. pylori infection (21). Whilst only a 
proportion of ulcer patients actually develop serious and costly complications, many are 
afflicted by recurrent episodes of ulcer relapse which results in ongoing demands on the 
health care system. Hence the potential economic burden of peptic ulceration is 
considerable, both in terms of the direct costs of providing medical care and in terms of 
the indirect costs resulting from lost productivity (22). Accurate diagnostic tests are thus 
important in order to set up targeted intervention (e.g. antibiotic therapy). H. pylori can be 
diagnosed by using invasive techniques such as endoscopy and biopsy for histology, 
culture and rapid urease test and non-invasive techniques like serology,13C-urea breath 
test (13C-UBT) and stool antigen tests (SAT) (23). The choice of the right test should be 
based on the prevalence of the infection in the population, the presence of alarm 
symptoms, the “likelihood ratio” for a positive and a negative test and the costs and 
availability of the test in different settings. 
1.5.1 Endoscopy 
Upper gastrointestinal endoscopy is an expensive and unpleasant procedure that carries 
the risk of hemorrage and perforation, but is still the only procedure that permits the 
definitive diagnosis of the infection and its complications. The European Helicobacter 
Study Group (EHSG) Maastricht V guidelines recommended that a “test and treat” 
strategy (TTI: testing for colonization by non-invasive screening and treating if colonization 
is confirmed) is optimal in patients with uninvestigated dyspepsia in areas of high 
Helicobacter prevalence (24). 
Unfortunately, TTI approach can’t define a definitive diagnosis of ulceration as opposed to 
non ulcerated dyspepsia; therefore endoscopy should be considered only in patients with 
alarm symptoms (weight loss, bleeding, anemia) of any age and patients aged more than 
55 years (25). In recent years there has been increasing interest in the goal of endoscopic 
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“in vivo” histology using narrow-band imaging, chromoendoscopy and confocal laser 
endomiscroscopy (26). In fact the mucosal surface and subsurface can be examinated in 
detail for the presence of characteristic pathological features and detection of H. pylori 
based on the assumption that the endoscopic appearence of the normal stomach is of a 
regular arrangements of epithelial cells, gastric pits and subepithelial capillaries while in H. 
pylori gastritis, the collecting venuoles cannot be seen or the gastric pits are enlarged with 
surrounding erithema and the normal capillary network is lost. 
 
1.5.2 Rapid Urease Test (RUT) 
Urease is one of the most abundant proteins produced by H. pylori, comprising about 10-
15% of the total protein content, testifying its importance to the organism. Urease is found 
on the surface of the organism. The gastric biopsy test is based on the activity of the H. 
pylori urease enzyme, which splits the urea test reagent to form ammonia. Ammonia 
increases pH, which is detected by the indicator phenol red. Many different commercial 
RUT test are available (gel-based, paper-based and liquid-based) results are available 
after 1 h or up to 24 h depending in part on the format of the test and the number of 
bacteria in the biopsy specimen. All the commercial RUT tests have specificities of 95-100% 
but the sensitivity is slightly less at 85-95%. The sensitivity is affected mainly by the 
number of bacteria in the biopsy, but also presence of blood, achlorhydria and proton 
pump inhibitors (PPI) therapy. 
 
1.5.3 Culture 
H. pylori can be cultured from gastric biopsies. Biopsies collected for bacterial culture are 
immediately streaked onto commercial selective medium Pylori Agar and the plates are 
incubated under microaerobic conditions at 37°C for 72 h. Once incubated, the colonies 
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resembling H. pylori are identified by Gram stain and by oxidase, catalase and urease 
tests. Suspensions from the primary plates are prepared in sterile saline solution to 
McFarland opacity standard 4 (approximately 108 cells ⁄ mL) to perform an E-test.  An agar 
plate is streaked in three directions with a swab dipped into each bacterial suspension to 
produce a lawn of growth, an E-Test strip is placed each onto a separate plate, which is 
immediately incubated in a Microaerophilic atmosphere at 37°C for 72 h. Isolated strains 
are tested for primary Clarithromycin (CLA), Metronidazole (MTZ) and Levofloxacin (LVX) 
resistance using break points for the minimal inhibitory concentration (MIC) of >0.5, >8 
and >1 mg⁄ L, respectively, according to the updated recommendations of the European 
Committee on Antimicrobial Susceptibility Testing (27). 
As the prevalence of antibiotic resistance increases globally there is a strong argument on 
performing culture and sensitivity testing after the first treatment failure (to prevent 
emergence of double resistance to CLA and MTZ) and certainly after the second; indeed, 
some would argue that it should be performed at the initial diagnosis in areas of high 
resistance prevalence. Moreover, it has to be emphasized that susceptibility to a full range 
of antibiotics can only be tested by cultures. However, culture needs qualified and skilled 
operator to reach high performance and it is quite invasive and expensive. 
 
1.5.4 13C-Urea Breath test (13C-UBT) 
The 13C-Urea Breath Test (13C-UBT) is one of the main non-invasive methods for H.pylori 
infection diagnosis.13C-UBT can detect the presence of H. pylori indirectly by 
demonstrating the presence of marked carbon dioxide in subject’s breath by 
somministrating 13C labelled urea. In fact the presence of urease due to H. pylori elicit the 
splitting of urea and carbon dioxide which diffuses into the epithelial blood vessels and 
appears in the patient’s breath. The isotopic labelled urea is usually given to the patient 
with a test meal to delay gastric empting and increase contact time with the mucosa. 13C-
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UBT has a very high sensitivity and specificity, ranging from 95 to 97 %; however it may 
not be reliable in assessing patients who have had a gastric surgery or in patients who 
have been on proton pumps inhibitors. 13C and 14C-urea breath test are similar, except 
that 13C is a non radioactiive isotope of 12C hence usable for children and pregnant women 
(28).⁠ 
 
1.5.5 Stool antigen test (SAT) 
An enzimatic immunoessay that detects the presence of H. pylori antigen in stool 
specimens has recently become available. This test is comfortable for the patient and very 
useful with the pediatric patients. Recent transition from polyclonal to monoclonal has 
improved considerably this technique. A metanalysis showed that Monoclonal SAT is an 
accurate noninvasive method both for the initial diagnosis of H. pylori infection and for the 
confirmation of its eradication after treatment. The monoclonal technique has higher 
sensitivity than the polyclonal one, especially in the post-treatment setting (29). 
Most of the studies have suggested that the accuracy of this test is similar to that of the 
13C-UBT for initial diagnosis of infection and are both recommended by both the National 
Istitute for Health and Clinical excellence (NICE) in the UK and in the EHSG Maastrict V 
Consenus Statement. A positive stool test 7 days after completion of treatment is 
predictive for failed eradication (30). 
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1.6 Helicobacter pylori management 
Eradication of H. pylori prevents development of pre-neoplastic changes (atrophic gastritis 
and intestinal metaplasia) and reduces the risk of gastric cancer as evidenced by non-
randomized controlled studies in animals and humans. Several studies show regression of 
pre-cancerous lesions, or at least, slower progression as compared with control groups 
after H. pylori eradication. Moreover, MALT lymphoma shows strong epidemiological 
association with H. pylori infection and the eradication of H. pylori can reverse this 
condition (11). A TTI strategy is appropriate for uninvestigated dyspepsia. This approach 
is subject to regional H. pylori prevalence and cost-benefit considerations. It is not 
applicable to patients with alarm symptoms or older patients.  In areas of low H. pylori 
prevalence (<20%), PPI empirical therapy or a TTI strategy are considered to be 
equivalent options. Screening for H. pylori may not be appropriate when the population 
prevalence of H. pylori decreases to 10% as this may result in a significant proportion of 
false positives, leading to unnecessary treatments. This is more likely to occur with the 
less sensitive and specific serology tests than with the 13C-UBT (31) . 
In patients on long-term acid suppressive therapy, it is advisable to eradicate H. pylori in 
case there is development of atrophic gastritis caused by bacterial overgrowth. Moreover, 
the relationship between H. pylori Infection and non-steroidal anti-inflammatory drugs 
(NSAIDs) in gastroduodenal pathology is complex: the risk of ulcer bleeding when both 
factors are present increases, but results of H. pylori eradication in NSAIDs users are 
conflicting. However, in patients with H. pylori infection who are naive NSAIDs users, the 
eradication therapy is superior to placebo in preventing peptic ulcer and upper 
gastrointestinal bleeding. Instead for high risk patients the eradication of the organism 
should be mandatory. 
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1.6.1 Antibiotics 
H. pylori is very sensitive to many antibiotics, although over the past two decades there 
has been an increasing problem with the development of resistance. Antibiotic sensitivity 
testing is important to check sensitivity before treatment and to assess local, national or 
international resistance rates. Several antibiotics are involved in H. pylori eradication 
regimens, most of them are now less effective due to the development of antibiotic 
resistance that is in turn related to the over-mis use of antibiotics therapies worldwide. 
Eradication regimen are based mainly on regimens containing: penicillin, macrolide, 
fluorquinolone and imidazole: 
- Amoxicillin (AMX) is a B lactam antibiotic that binds to cell wall transpeptidase, inhibiting 
the making of cell wall. Resistance to B lactam antibiotics is due to B lacatmasase 
production or an altered penicllin-binding protein. 
- Clarithromycin (CLA) is another key antibiotics in H. pylori eradication regimens, it is a 
macrolide and inhibits protein synthesis by binding to the 23SrRNA component of the 50S 
subunit of the ribosome. CLA resistance is due to point mutations in 23S rRNA gene. 
Since now several point mutations have been identified which include A2143G, A2142G, 
A2142C, A2115G, A2142T, A2223G, C2147G, C2694A, C2611A C2195T, C2245T, 
G224A, G2141A, T2190C, T2182C, T2117C, T2289C. The first three above mentioned 
mutations (A2143G,  A2142G,  A2142C) represent >90% of the observed mutations with 
confirmed clinical relevance (32).  
- Metronidazole (MTZ) is also involved in eradication of the bacteria. It is a 5-
nitroimidazole that is activated by H. pylori nitroreductase enzyme, and his resistance 
varies between 15-78%.  
- Levofloxacin (LVX), a fluoroquinolone used in rescue therapeutic regimens, interacts 
with type II topoisomerases preventing the unwinding of DNA and DNA replication. It is 
used normally as a second line treatment. 
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1.6.2 Proton pump inhibitors (PPI) 
These agents comprehend omeprazole, esomeprazole, lansoprazole, pantoprazole and 
raberprazole. PPI are always associated to antibiotics in eradication regimens. Their 
mechanism provides antisecretory activity by blocking the H/K ATPase proton pump in 
parietal cells (33). PPI also enhance the pharmacodynamics of antibiotics due to their 
inhibitory effect on acid secretion. Plus, PPI are capable also of antimicrobial activity 
themselves against H. pylori. A consideration must be made upon metabolism of PPI 
which is dependent upon polymorphisms in the cytochrome P450 2C19, leading to high or 
low metabolizers. High metabolizers (patiens with a rapid eliminarion of PPI) presents a 
lower eradication rate, this is the reason why high dose PPI are usually suggested in 
association with antibiotic therapy. 
 
1.6.3 Current therapies 
EHSG suggests one week triple therapy (PPI, CLA plus AMX or MTZ) for seven day in 
those areas where CLA resistance is lower than 15-20 % (34), and is being currently 
prescribed by 85%, 84% and 67% physicians in Italy, Israel  and USA. 
A prolonged 14 day regimen or a 10-14 day quadruple therapy (PPI + Bismuth + MTZ + 
Tetracycline administered for 7-10 days) should be administered when bacterial 
resistance is higher (34). Unfortunately a metanalysis has shown that the 14-day triple 
therapy offers only a modest improvement (87.7% of eradication) over the 7 day regimen 
(79.7% of eradication) in terms of H. pylori eradication rates (35). One of the main reasons 
for the poor performance of treatments is the increasing number of H. pylori strains 
resistant to antibiotics especially CLA and MTZ. Indeed antimicrobial resistance is 
responsible for the declining rates of H. pylori eradication seen in many countries (36).⁠ 
However the situation changed in 2000 with the incoming of a new sequential treatment 
regimen as alternative to CLA triple therapy, reaching an average of 92% eradication rate 
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(37). The sequential regimen is a simple dual therapy (a PPI plus AMX 1g, both given 
twice daily) for the first 5 days, followed by a triple therapy (PPI, CLA 500 mg and 
tinidazole, all given twice daily) for the remaining five days (37). 
The reason for this sequence is that dual therapy administered for less than 7 days is able 
to achieve a cure rate up to 50%, affecting the bacterial load which is inversely related to 
the efficacy of triple therapy, that needs a low bacterial load to favour its efficacy. 
Moreover, AMX is able to prevent selection of secondary CLA resistance by weakeing 
bacterial cell wall and preventing the development of efflux channels (38). 
A recent systematic review and meta-analysis compared sequential therapy to established 
and newer therapies. The overall eradication rate for sequential therapy was 84.3% (95% 
CI, 82.1–86.4%), confirming its high efficacy despite a decrease in eradication rate during 
years due to the increasing antibiotic resistance. Sequential therapy was superior to 7 
days of CLA triple therapy (RR 1.21; 95% CI, 1.17–1.25). However, sequential therapy 
was only marginally superior to 10 days of CLA-based triple therapy (RR, 1.11; 95% CI, 
1.04–1.19) and was not superior to 14 days of CLA-based triple therapy (RR, 1.00; 95% 
CI, 0.94– 1.06) or 10–14 of bismuth quadruple therapy (RR, 1.01; 95% CI, 0.95–1.06)  
(39). Ultimately, another study from Taiwan suggested that eradication rates might be 
improved by extending the duration of sequential therapy to 14 days  (40). 
 
1.6.4 approach to resistance 
⁠In settings with high CLA resistance the efficacy of triple and sequential therapy is 
undermined; plus MTZ resistance undermines the efficacy of sequential therapy, and dual 
CLA and MTZ resistance undermines the efficacy of sequential, hybrid and concomitant 
therapy(24).⁠ Therefore, the choice of therapy should be based on the frequency of MTZ 
and dual CLA and MTZ resistance. 
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In geographical areas where MTZ resistance is almost negligible (eg, Japan), replacing 
CLA for MTZ in triple therapy (ie, PPI-MTZ-AMX) still shows excellent cure rates (41). 
In regions with high CLA resistance (15–40%) but low to intermediate MTZ resistance 
(<40%) (a pattern common for most central and southern European countries and the 
USA) (42)(43), non-bismuth quadruple concomitant therapy, prescribed for 14 days (44),  
can be an effective alternative. 
Non-bismuth quadruple therapy or “concomitant” therapy is the combination of PPI-CLA-
AMX-nitroimidazole administered together. A recent meta-analysis of randomized trials 
showed that the eradication rate with non-bismuth quadruple therapy was 90% compared 
to 78% with triple therapy (45).  Therefore concomitant therapy seems to be a valid 
alternative to triple therapy in those areas where bismuth is not available.  
In areas of high dual CLA and MTZ resistance, bismuth quadruple therapy (BQT) is the 
recommended first-line treatment.   Ideally, CLA should be avoided and a combination of 
alternative antibiotics for which resistance does not become problematic (eg, amoxicillin, 
tetracycline, furazolidone, rifabutin) or can be successfully overcome with increasing 
doses, dosing interval and duration (eg, MTZ) should be recommended (24). If bismuth is 
not available in high dual CLA and MTZ resistance areas, LVX, rifabutin, and high dose 
dual (PPI+AMX)  treatments can be considered (24).                  
 
1.6.5 Other factors affecting treatment response 
1.6.5.1 Patient’s adherence to treatment 
In addition to antimicrobial resistance, several other factors affects the eradication rate; 
patients taking less than 80% of their treatment regimen have a high rate of treatment 
failure, which is strongly associated with other anti-microbial resistances. It should always 
be emphasized to the patient that successful eradication depends on full compliance with 
the treatment. A least a short time should be taken to counsel the patient, explaining the 
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procedures involved in taking complicated drug therapies and describing the side-effects 
to improve the outcome. 
1.6.5.2 Side effects and smoking habits 
Up to 50% of patients have mild side-effects while taking H. pylori treatment and less than 
10% of patients stop treatment because of side- effects. Some of the most common side-
effects are metallic taste, especially by using MTZ or CLA, constipation while taking 
bismuth based treatments, and diarrhea or stomach cramps. Smoking reduces the 
success rate of standard triple therapy mainly altering antibiotics delivering into the gastric 
mucosa. Indeed, reduction in gastric blood flow and mucus secretion or an increased 
acidsecretion can reduce the antibiotic activity. 
 
1.7 Aim and objective 
 
H. pylori infection is a major cause of gastric ulcer disease and gastritis in humans and is 
a risk factor for the development of gastric cancer.  Current guidelines recommend that all 
patients with documented H. pylori infection should be treated with an appropriate 
antibacterial therapy. CLA-based triple therapy is commonly used as a first line treatment; 
however, resistance of H. pylori to CLA has been gradually increasing worldwide (36) (39). 
Treatment failures associated with resistance to CLA were reported and genetic analysis 
of resistant strains isolated from patients who failed primary CLA-based treatment, 
identified mutations in the 23S ribosomal RNA (rRNA) as the predominant cause of 
resistance. In particular, point mutations in positions 2143 (A to G) and 2142 (A to 
G/C),(46). A lower prevalence of A2142G/C mutation has been described, but these 
mutations are also commonly found in patients in whom CLA-based treatment failed to 
eradicate the infection, highlighting that these mutations are due to selective pressure 
under antibiotic therapy. Testing for antibiotic sensitivity has been complicated for H. pylori 
due to the necessity to perform culture and chemosusceptibility test, which require 
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additional biopsies and specific laboratory competence. The approach of using a stool 
specimen in a molecular test for CLA resistance has therefore been proposed (47).. To 
date, there is very limited data on use of such approach in clinical research. It appears 
that, while the specificity of the molecular test has been consistently very high (more than 
95%), the achievement of a high sensitivity remains very challenging. 
Therefore, the aim of this study was to evaluate the feasibility of using stool samples to 
detect the presence of H. pylori DNA, while concurrently detecting the presence of 
mutations associated with the resistance to CLA. 
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Chapter 2- Methods 
2.1 Samples and extraction method 
Stool samples were acquired from a population of patients tested for H. pylori infection in 
Bologna, Italy. Samples were collected, frozen and kept at -20 °C prior to testing.  Patients 
were diagnosed as H. pylori positive or negative according to concordant results of the 
composite reference method (CRM: 13C-UBT, RUT, histology and culture) as the gold 
standard (48)(49). Total DNA was extracted from 292 raw stool samples using the 
QIAamp Fast DNA Stool Kit (QIAgen) where the workflow matched the protocol for human 
DNA isolation (instead of the pathogen protocol) as provided by the manufacturer’s 
instructions.  A qPCR exogenous control (Bioline Cat #BIO-11025) made up of a known 
concentration of bacterial DNA was spiked into the lysis buffer just prior to extraction.  The 
exogenous control was applicable for high annealing temperature Polymerase Chain 
Reaction (PCR) and was added during the lysis step of the DNA extraction to monitor 
extraction efficiency and the presence of inhibitors. Extracted DNA was stored at -20 °C 
prior to qPCR testing. 
2.2 DNA extraction and purification 
The collected stools were defrosted naturally, 200mg of the specimen were put in 1ml of 
InhibitEX buffer, after a strong passage into vortex and 1 min in the centrifuge, 
proteinaseK was used to to purify nucleic acid preparations by digesting the contaminating 
proteins.  
Buffer AL was added and throughout an incubation at 70°C for 10 min and the subsequent 
addition of ethanol, the DNA has been released in the solution making possible his 
purification and isolation (through successive washes with buffers AW1 and AW2) in order 
to amplify it with PCR. 
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2.3 Molecular detection 
TaqMan real-time PCR amplification was used to detect the presence of H. pylori as well 
as predict the phenotype of the organism and the related outcome of patients treated with 
CLA.  Extracts were amplified on the QIAgen Rotorgene.  
The PCR master mix was comprised of H. pylori/Resistance primer set (Meridian 
Bioscience; Cat#ASR100), H. pylori probe (Meridian Bioscience; Cat#ASR101) and H. 
pylori CLA Resistance (HPCR) probe (Meridian Bioscience; Cat#ASR102) and was 
assembled into a final PCR reaction as follows: 100nM of each TaqMan probe targeting 
the H. pylori 23S rRNA in the green (Emission 510nm) and red (Emission 660nm) 
channels; 400nM of ASR primers; 40nM of control primers (Bioline Cat #BIO-11025 
includes primers and probe) and 100nM control probe (Emission 610nm), 1x SensiPLUS 
mastermix (Bioline Cat #BIO-11021).   
Typically, 20 µL of purified DNA sample was added to the amplification mixture.  
Molecular grade water was added to make up a total volume of the PCR reaction to 50 µL.  
The PCR amplification was performed with the following parameters: Initial hold 
temperature 95 oC for 10 min, then 50 cycles of 95 oC for 20 sec and 65 oC for 60 sec; 
followed by a melting protocol measuring fluorescent intensity of the red probe (emission 
660nm) in the temperature range of 52 oC-70 oC; (10 second wait between intervals; 1oC 
increase each cycle). 
 
2.4 Analysis of PCR 
PCR results for detection of H. pylori was calculated based on CRM as the comparator 
method.  The CLA resistance prediction due to the presence of 23S rRNA mutations was 
performed in parallel with detection of H. pylori.  Amplification observed in the green 
channel translated to the presence of H. pylori in the purified DNA from stool.  Presence of 
the amplification in the red channel was used for making a prediction of CLA resistance or 
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susceptibility. Two alternative approaches were employed to analyse amplified DNA and 
make a determination of CLA susceptible or resistant for each sample: 
1) The first approach comprised of using differential fluorescent signal analysis and 
finding the derivate function for both the green and red signal for every cycle.  The 
difference between the green and red signal determined the resistance prediction.  If the 
red signal had an attenuated result and, therefore, a positive delta from the green signal, 
the sample was called as containing mutation conferring clarithromycin resistance.  If the 
red signal was the same or, in most cases, stronger than the signal in the green channel, 
the result would be a negative delta from the green signal.  The sample was then deemed 
as not containing targeted mutations and susceptible to CLA.  Figure 1 shows an 
example of a sample that was predicted to be resistant to CLA and a sample that was 
predicted to be susceptible to CLA. 
2) The second approach was to analyse the H. pylori amplified target and make a 
prediction of resistance was by melting curve analysis in the temperature range of 52°C-
72°C.  A 10 second wait was programmed between intervals and temperature increased 
1°C with each cycle.  When a single peak was observed at temperatures lower than 60°C, 
typically 54-56°C, the sample was deemed as containing mutations conferring resistance 
to CLA.  When a single peak was observed above 60°C, typically 63-65°C, the sample 
was deemed as lacking targeted mutations and susceptible to CLA.  Figure 2 shows 
examples of typical melt profiles produced by the analysis of samples comprising wild type 
sequences and different CLA-resistant mutations.  Samples demonstrating amplification in 
green channel and no amplification in red channel were called as H. pylori positive and 
indeterminate for the presence of CLA-resistant mutations. 
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2.5 Purification of PCR products and sequencing 
 PCR products were purified using Macherey-Nagel’s NucleoSpin Gel Purification kit (Cat 
#740609).  The identity of amplified PCR products was confirmed by Sanger Sequencing.  
GeneWiz [NJ, USA] performed bi-directional sequencing to confirm the genotype. 
 
2.6 Reference testing 
Patients were tested, in parallel to molecular testing, by 13C-UBT and subjected to 
esophagogastroduodenoscopy (EGD) followed by RUT, histology and culture, obtaining a 
consensus patient infection status.  
PCR data were compared to the outcome of the eradication treatment for a subset of 
patients treated with clarithromycin as part of a sequential therapy (PPI plus AMX 1g, both 
given twice daily for the first 5 days, followed by a triple therapy (PPI, CLA 500 mg and 
tinidazole), all given twice daily for the remaining five days. All patients underwent a 
standard 13C-UBT after an overnight fast at the beginning and 4 to 6 weeks following the 
end of antibiotic therapy to assess the eradication status (48). 
 
2.7 Statistical analysis 
Means and their 95% confidence intervals were calculated.  Comparisons among patient 
subgroups were performed using the chi-square. Test accuracy was calculated with “2x2” 
table method (MEDCALC 17.2). A P level less than .05 was considered significant. 
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Chapter 3- Results 
Stool specimens were collected from August 2016 to March 2017 and tested by PCR 
within a month of collection.  The optimal amount of stool producing the best sensitivity of 
detection was determined as approximately 200mg (180-220mg, same as manufacturer’s 
instructions) from preliminary experiments. 
3.1 PCR versus CRM 
Out of 292 total stool samples from H. pylori patients, 228 were positive by CRM and by 
the novel PCR test.  Two samples were invalid by PCR and were excluded.  PCR resulted 
in approximately 93.8% (CI: 90.0-96.5%) (228/243) sensitivity in comparison with the 
CRM. Specificity was approximately 77.6% (CI:63.3-88.2%) however, the current study 
targeted predominantly positive patient population in order to establish clinical sensitivity 
of the stool PCR method, therefore before drawing conclusions regarding clinical 
specificity a higher number of negative samples should be included. According to the 
previous results the positive predictive value (PPV) was 95.4% (CI:92.5-97.2%) while the 
negative predictive value was 71.7% (CI:60.2-80.8%) with an overall accuracy of the PCR 
test of 91.1% (CI:87.2-94.1%). The diagnostic outcome for H pylori detection for PCR are 
shown in Table 1.  
3.2 PCR versus Sequencing for Clarithromycin susceptibility prediction 
The CLA susceptibility prediction from PCR was verified by sequencing that established 
the identity of nucleotides in positions 2142 and 2143 of the 23S rRNA gene. The 
genotype for all samples positive by PCR that produced definitive sequencing results was 
therefore analysed. In total 239 samples were considered (228 positive at CRM and PCR 
and 11 negative at CRM but positive at PCR). However 26 samples were not able to be 
included in the genotypic analysis due to unevaluable results from either PCR and/or 
sequencing: 7 sample were not sequenced or resulted in a failed sequence;  4 sequences 
were unreadable;  9 samples were deemed indeterminate or containing mixed alleles by 
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sequencing;  4 samples were discrepant by melt and differential signal analysis using 
PCR determination;  2 were indeterminate for genotype by PCR. Therefore 213 samples 
were considered in the final comparison between PCR performance and sequencing 
(Table 2). 
Out of 213 remaining positive samples, 77 (36.1%) contained mutations and 136 (63.8%) 
contained the wild type sequence. PCR correctly identified 133 out of 136 samples (97.8%) 
containing wild type (CLA sensitive) sequence and 76 out of 77 (98.7%) samples 
containing mutations with a total accuracy of 98.1% (CI:95.2-99.4%).  
Among the mutations, 3 samples contained A2142C sequence (genotype CAA), 19 
samples contained A2142G sequence (genotype GAA), and 55 samples contained 
A2143G sequence (genotype AGA). One sample that was predicted by PCR to be a wild 
type (genotype AAA), contained a mutation at the A2143G position (genotype AGA). 
Three samples that were predicted by PCR to be resistant were wild type (genotype AAA). 
In our population the most frequent mutation was A2143G that was observed in 55 cases; 
54 out of 55 were correctly identified by PCR. The A2142G mutation was detected in 19 
cases, all of them were correctly identified by PCR. The A2142C mutation was detected in 
3 cases in concordance with PCR. A discrepancy between sequencing and PCR results 
was detected only in 4 cases. The PCR test total accuracy was 98.1% (Table 3). 
3.3 Correlation between genotype prediction by PCR and phenotype  
168 culture were available out of 213 samples with PCR prediction and sequencing 
results. PCR sensitivity (ability to identify resistant strains) and specificity (ability to identify 
susceptible strains) were 60.4%(CI:50.4-69.7%) and 93.5% (CI:84.3-98.2%) respectively 
(Table 4). Considering culture as the gold standard, PCR accuracy was 72.6% (CI: 
65.2%-79.2%). 
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3.4 Correlation between genotype prediction by PCR and eradication 
Eradication results were available for 121 patients treated with therapeutic regimens 
containing clarithromycin (Table 5). 
Correlation between genotype prediction by PCR and eradication of patients treated with 
clarithromycin was 83.5% . 
Potential cross-reactivity of the PCR toward different Campylobacter species commonly 
found in non-diarrheal stool were also evaluated.  At the concentration of 106 genomic 
copies in the reaction analytical specificity was confirmed with the various Campy species. 
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Chapter 4- Discussion 
According to our findings, these data demonstrate that H. pylori DNA can be detected in 
human stool specimens with high sensitivity and therefore this test can be used to 
determine the presence of H. pylori with a performance similar to that of other direct 
assays, such as the SAT or UBT (48). More importantly, genotypic resistance to 
clarithromycin can be detected, enabling the right therapeutic approach to be chosen 
without a biopsy sample obtainded during an invasive procedure such as gastroscopy. 
Moreover, culture and antibiotic susceptibility test are not always feasible and skilled 
biologists are needed. Culture test is also difficult to perform, expensive and time 
consuming (5-7 days to obtain results) and nearly 20% of cultures are not diagnostic (no 
growth or overgrowth of other bacteria and fungi). This finding confirms previous reports 
describing the use of PCR detection and assessment of clarithromycin sensitivity using 
stool specimens (27).  
The design for this PCR test allows for multiple ways to analyze the data. Melting of the 
red probe targets the mutation sites associated with resistance. The proprietary nature of 
the TaqMan probes improves melt resolution, enabling a CLA susceptibility prediction 
(49). The prediction based on a melting curve can be determined immediately upon 
analysis with a specific software. Alternatively, resistance can be predicted using 
fluorescent signal analysis differentiation as described in “Materials and Methods” (50). 
Discrepancies between sequencing results and PCR prediction of resistance may be due 
to nonspecific traces and biologists interpretation. This study also shows a significant 
correlation between the detection of 23S rRNA mutations conferring resistance to 
clarithromycin and the final eradication status of the patient. Taking into account the 
expected bias of this study due to the fact that the majority of the patients predicted to be 
resistant were not treated with clarithromycin because they were previously treated with 
first line eradication therapy for H. pylori eradication (also called “not-naïve” patients), the 
drop in the response rate from 93% (93 out of 100 patients with predicted CLA-sensitive 
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organisms were eradicated) to 62% (13 out of 21 patients with 23SrRNA point mutations 
were eradicated) suggests the beneficial impact of the PCR test in the selection of the 
appropriate therapy. This PCR test using stool specimens is capable of sensitive detection 
of H. pylori DNA in stool while simultaneously detecting mutations causing clarithromycin 
resistance. This is very important as there is a significant correlation between the 
presence of such mutations and the outcome of clarithromycin-based eradication 
treatment. The results of this study suggest that stool can be used to determine resistance 
with a high correlation to eradication status. 
This assay can be used as a stand-alone screening tool, since it can detect the presence 
of H. pylori as well as resistance, but is most cost-efficient once negative patients are 
eliminated by a stool antigen test or UBT. Both approaches quickly eliminate negative 
patients from further analysis. (48) (51) 
This stool/PCR test has also the potential to reduce health care costs with an updated 
algorithm. A biopsy sample requires the patient to return to the health care provider for an 
invasive procedure if treatment is unsuccessful (24). The PCR test option with the 
noninvasive sample can significantly reduce the need for biopsy samples, currently used 
to determine resistance in patients who do not need to undergo upper endoscopy 
according to clinical guidelines (52). 
However, further clinical studies with a more balanced patient population and with 
investigators blinded to the outcome of the resistance determination, would define the true 
clinical value of the stool PCR test. The high analytical specificity and clinical sensitivity of 
this molecular H. pylori resistance assay provide a strong likelihood of accurately 
predicting eradication of infection by CLA therapy. 
In conclusion this PCR test using stool specimens is capable of sensitive detection of H. 
pylori DNA in stool while simultaneously detecting presence of mutations causing 
clarithromycin resistance.  There is a significant correlation between the presence of such 
mutations and the outcome of clarithromycin-based eradication treatment but furhter 
clinicaltrials are needed to strengthen these findings. 
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Definitions 
 
Term Explanation 
AMX Amoxicillin 
BabA   blood group antigen-binding adhesion 
Cag A cytotoxin associated gene A 
Cag Pai cytotoxin associated pathogenicity island 
CLA Clarithromycin 
CO2       Carbon Dioxide 
CRM Composite Reference Method 
13C-UBT 13C-Urea Breath Test 
EGD Esofagogastroduodenoscopy 
EHSG European Helicobacter Study Group 
IARC International Agency for Research on Cancer 
Le
b 
Lewis b blood group antigen 
sialyl-Le
x 
Sialyl-Lewis x blood group antigen 
LVX Levofloxacin 
LPS         Lipopolysaccharide 
MALT  Mucose Associated Limphoid Tissue 
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MIC Minimal Inhibitory Concentration 
MTZ Metronidazole 
NSAIDs Non-steroidal anti-inflammatory drugs 
PCR Polymerase Chain Reaction 
PPI  Proton Pump Inhibitor 
RUT  Rapid Urease Test 
Sab A Sialic acid-binding adhesin 
SAT  Tool antigen Test 
TTI Test and treat 
Vac A Vacuolizing associated gene A 
 
  
39 
 
Tables 
 
 CRM+ CRM- TOT 
PCR+ 228 (93.8%) 11 (22.4%) 239 (81.8%) 
PCR- 15 (6.2%) 38 (76.6%) 53 (18.2%) 
 243 49 292 
 
Table 1: diagnostic outcome of PCR for H. pylori detection compared to CRM.  
  Concordance: 91.1% Cohen’s K concordance 0.69 (good) 
 
 Seq R Seq S TOT 
PCR R 76 (98.7%) 3 (2.2%) 79 (37.1%) 
PCR S 1 (1.3%) 133 (97.8%) 134 (62.9%) 
 77 136 213 
 
Table 2: diagnostic outcome of PCR for H. pylori detection compared to sequencing.  
  Concordance: 98.1% Cohen’s K concordance 0.96 (excellent) 
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No. of samples Genotype  PCR prediction 
133 (62.4%) AAA susceptible 
54 (25.3%) AGA resistant 
19 (8.9%) GAA resistant 
3 (1.4%) CAA resistant 
3 (1.4%) AAA resistant 
1 (0.5%) AGA susceptible 
 
Table 3: The CLA susceptibility prediction from PCR verified by sequencing that established the 
identity of nucleotides in positions 2142 and 2143 of the 23S rRNA gene. 
 Culture R Culture S TOT 
PCR R 64 (60.4%) 4 (6.5%) 68 (40.5%) 
PCR S 42 (39.6%) 58 (93.5%) 100 (59.5%) 
 106 62 168 
 
Table 4: Correlation between genotype prediction by PCR and phenotype (culture). 
    Concordance: 72.6% Cohen’s K concordance 0.48 (moderate) 
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 Not eradicated Eradicated TOT 
PCR R 8 (53.3%) 13 (12.3%) 21 (17.3%) 
PCR S 7 (46.7%) 93 (87.7%) 100 (82.7%) 
 15 106 121 
 
Table 5: Correlation between genotype prediction by PCR and eradication. 
    Concordance: 83.5 % Cohen’s K concordance 0.35 (moderate) 
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Figures 
 
 
 
 
 
Figure 1: Fluorescent signal analysis for (a) wild type and (b) a mutant genotype. 
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Figure 2: Melt curve analysis for wild type, A2141G, A2142C, and A 2143G mutant genotypes  
associated with resistance to clarithromycin. 
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